Last reviewed · How we verify
Placebo to Oseltamivir
This is a Phase 3 clinical trial comparing placebo to oseltamivir (Tamiflu), an antiviral neuraminidase inhibitor used to treat influenza.
This is a Phase 3 clinical trial comparing placebo to oseltamivir (Tamiflu), an antiviral neuraminidase inhibitor used to treat influenza. Used for Treatment of acute uncomplicated influenza A and B infection, Prophylaxis of influenza in exposed individuals.
At a glance
| Generic name | Placebo to Oseltamivir |
|---|---|
| Sponsor | Guangdong Raynovent Biotech Co., Ltd |
| Drug class | Neuraminidase inhibitor |
| Target | Influenza neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Oseltamivir is a neuraminidase inhibitor that blocks the viral neuraminidase enzyme, preventing influenza virus particles from being released from infected cells and reducing viral spread. The trial is evaluating oseltamivir's efficacy and safety compared to placebo in treating or preventing influenza infection. This is a comparative effectiveness study rather than a novel drug development program.
Approved indications
- Treatment of acute uncomplicated influenza A and B infection
- Prophylaxis of influenza in exposed individuals
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Bronchitis
Key clinical trials
- Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting (PHASE3)
- Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza (PHASE3)
- Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza (PHASE3)
- Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza (PHASE3)
- Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza (PHASE3)
- Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) (PHASE1)
- Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza (PHASE2, PHASE3)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Oseltamivir CI brief — competitive landscape report
- Placebo to Oseltamivir updates RSS · CI watch RSS
- Guangdong Raynovent Biotech Co., Ltd portfolio CI